The global neoantigen cancer vaccine market was valued at USD 24.4 million in 2022, and it will advance at a 67.6% compound annual growth rate, to touch USD 1,322.8 million, by 2030.
The key reasons for paying toward the industry advance are the growing research activities and rising cases of cancer throughout the world. Because of the growing importance of modified cancer treatments, medicinal makers are focusing on R&D to fulfill the remaining and potential demand for neoantigen cancer vaccines.
In 2022, the nucleic acid vaccine category dominated the industry, with a share of 55%, as medication businesses are actively participating in raising effective and cutting-edge vaccines on the basis of nucleic acid.
For example, In December of 2022, at the World Vaccine and Immunotherapy Congress in San Diego, IMUNON Inc. presented data on SARSCo2 using POLUNCINE modality and proof of concept for rodents and nonhuman primates. PLACCINE is a non-viral and non-device plasmid DNA-based vaccine modality for infectious diseases and cancer that targets multiple antigens from a single vector.
In 2022, the lung cancer category dominated the industry, with a 30% income share. Smoking is one of the main reasons of lung cancer throughout the world. The occurrence of this illness is 2–5 times more advanced in advanced nations, like the U.S., Australia, Ireland, and New Zealand than emerging nations, like Niger, Gambia, and Nepal.
In men, the uppermost occurrence of lung cancer is witnessed in Eastern and Southern Europe, Polynesia and Micronesia, East Asia, and North America, while the charges are low in sub-Saharan Africa. In females, the maximum lung cancer occurrence rates are found in Northern Europe, North America, and New Zealand/ Australia.
North America accounted for the largest share in 2022, and it will remain the largest in the years to come. This is attributed to the surging incidence of different cancers and speedy innovation in the healthcare sector. Moreover, the increasing R&D activities will boost the regional industry, through the approval and production of new therapeutics in the years to come.
Additionally, the surging prevalence of pancreatic adenocarcinoma has resulted in the invention of new neoantigen therapies by biotechnology manufacturers, therefore boosting the progression of the industry in North America.
The APAC neoantigen cancer vaccine industry will witness the fastest growth in the coming years. This is primarily credited to the speedy upgradation in targeted immunotherapy, as a result of the surging number of research initiatives in the regional nations, mainly due to the increasing cases of cancer.
With the surging research activities, as well as the increasing prevalence of cancer all over the world, the neoantigen cancer vaccine industry will continue to advance in the years to come.